| __timestamp | Soleno Therapeutics, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2242216 | 18516000 |
| Thursday, January 1, 2015 | 4536244 | 34140000 |
| Friday, January 1, 2016 | 5184803 | 51872000 |
| Sunday, January 1, 2017 | 3068742 | 71772000 |
| Monday, January 1, 2018 | 7178000 | 97501000 |
| Tuesday, January 1, 2019 | 16267000 | 118590000 |
| Wednesday, January 1, 2020 | 23191000 | 169802000 |
| Friday, January 1, 2021 | 21453000 | 192507000 |
| Saturday, January 1, 2022 | 15265000 | 199563000 |
| Sunday, January 1, 2023 | 25189000 | 253598000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Xencor, Inc. has consistently outpaced Soleno Therapeutics, Inc. in R&D investment. From 2014 to 2023, Xencor's R&D expenses grew by over 1,270%, peaking at approximately $254 million in 2023. In contrast, Soleno's R&D spending increased by around 1,020%, reaching about $25 million in the same year. This significant difference highlights Xencor's aggressive strategy in pioneering new therapies. While both companies have shown growth, Xencor's larger financial commitment suggests a stronger focus on developing cutting-edge solutions. As the biotech industry continues to evolve, these investments could be pivotal in determining future market leaders.
Research and Development Expenses Breakdown: Amgen Inc. vs Soleno Therapeutics, Inc.
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and Soleno Therapeutics, Inc.
Research and Development Investment: Genmab A/S vs Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Xencor, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alpine Immune Sciences, Inc. and Xencor, Inc.
R&D Spending Showdown: Ultragenyx Pharmaceutical Inc. vs Xencor, Inc.
R&D Insights: How Rhythm Pharmaceuticals, Inc. and Xencor, Inc. Allocate Funds
Comparing Innovation Spending: Vericel Corporation and Xencor, Inc.
Research and Development Investment: Soleno Therapeutics, Inc. vs Geron Corporation
R&D Spending Showdown: Soleno Therapeutics, Inc. vs Amphastar Pharmaceuticals, Inc.
R&D Spending Showdown: Evotec SE vs Xencor, Inc.